Neurana Pharmaceuticals, a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced that Craig Thompson , President and Chief Executive Officer, will present at the Solebury Trout Private Company Showcase and participate in one-on-one meetings with investors. The conference takes place vi
| SAN DIEGO, Aug. 4, 2020 /PRNewswire/ -- Neurana Pharmaceuticals, Inc., a biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, today announced that Craig Thompson, President and Chief Executive Officer, will present at the Solebury Trout Private Company Showcase and participate in one-on-one meetings with investors. The conference takes place virtually on August 10th. The details of Neurana’s presentation are as follows: Date: August 10th, 2020 Presentation Time: 12:40 – 1:00pm Eastern Time Presentation Webcast URL: https://www.webcaster4.com/Webcast/Page/2408/36373 More information regarding the conference, can be found at: https://troutaccess.com/index.php/c/Summer2020PCS About Neurana Pharmaceuticals, Inc. Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, including acute, painful muscle spasms of the back. The company was founded in 2013 and is based in San Diego. Neurana’s lead development compound is tolperisone, a novel, non-opioid, non-drowsy, non-cognitive impairing treatment, which the company is developing for the large population of patients who experience muscle spasms. In May 2018, Neurana completed a $60 million Series A financing led by Sofinnova Ventures with participation from Longitude Capital, New Leaf Venture Partners and H.I.G. BioHealth Partners to fund the clinical development of tolperisone. For additional information, please visit www.neuranapharma.com.
SOURCE Neurana Pharmaceuticals, Inc. |
View original content:
